US Patent

US10881663 — Method of treating pain in elderly patients with mild renal impairment

Method of Use · Assigned to Baudax Bio Inc · Expires 2039-03-08 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating pain in elderly patients with mild renal impairment by administering meloxicam intravenously.

USPTO Abstract

The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3038 Mobic

Patent Metadata

Patent number
US10881663
Jurisdiction
US
Classification
Method of Use
Expires
2039-03-08
Drug substance claim
No
Drug product claim
No
Assignee
Baudax Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.